AtaiBeckley Shows 49% Improvement Rate in Phase 2a EMP-01 Anxiety Trial
AtaiBeckley reported that 49% of participants in its exploratory Phase 2a trial of EMP-01 for social anxiety disorder were rated “very much improved” or “much improved”, compared with 15% on placebo. This topline result highlights a potentially meaningful treatment effect in early-stage development.
1. Phase 2a Trial Overview
AtaiBeckley enrolled an exploratory cohort of patients with social anxiety disorder in its Phase 2a trial of EMP-01, measuring clinician-rated improvement. Participants receiving EMP-01 experienced a 49% rate of “much improved” or “very much improved” scores compared with 15% in the placebo arm.
2. Clinical Significance
The 34-percentage-point separation over placebo suggests a robust early efficacy signal that exceeds typical placebo responses seen in social anxiety studies, supporting EMP-01’s potential as a differentiated treatment.
3. Full Data Review and Future Plans
The company will analyze the complete Phase 2a dataset to confirm efficacy and safety trends before advancing EMP-01 into larger, randomized studies, with objectives to refine dosing and prepare for late-stage development.